TL;DR
Get your next haul delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Anthropic said Oct. 27 it acquired Mithril Medicine, a one-person biotech developing treatments for two rare forms of muscular dystrophy. Its founder used Claude to coordinate work across 11 outside labs, but the lead candidate has been tested only in mice; Anthropic says a human trial could begin as soon as late 2028.
Anthropic said Oct. 27 it acquired Mithril Medicine, a startup developing treatments for two rare forms of muscular dystrophy, bringing an early-stage drug operation inside the AI company. Mithril founder Cody Tranbarger used Claude to coordinate business and research work with 11 outside labs; the lead candidate has so far been tested only in mice.
Tranbarger, Mithril’s only full-time employee, used Claude to organize contracts, logistics and experiments, and delegated other parts of the business to the model, according to the report. Mithril took one candidate from an initial idea to what the report describes as promising results in mice in under 18 months. No human trial results are reported.
Anthropic said operating real drug programs gives it a way to assess where Claude performs well and where it fails. It also said the programs could provide examples to share with other biotechnology companies and, if the candidates succeed, give Anthropic medicines of its own. Tranbarger has joined Anthropic and plans to start several more programs.
The company said the work remains mostly preclinical and that it intends to extend Claude’s role as the programs move toward clinical trials. Anthropic said a drug could be ready for human trials as soon as late 2028. That is a projected timetable, not confirmation that a trial has been approved or will begin then.
Anthropic Tests AI in Drug Development
The acquisition moves Anthropic’s life-sciences ambitions beyond selling AI tools to researchers: the company will now operate drug programs and use them to learn how Claude performs in a complex, real-world research setting. That could give the company direct experience with the coordination and documentation involved in drug development, as well as potential drug candidates if the research works.
The distinction between supporting research and producing a medicine remains important. Mithril’s reported progress is in mice, and the program has not reached human testing. The acquisition is therefore a bet on applying Claude across early drug development, not evidence that an AI system has produced a treatment for patients.
For biotech companies, the effort could offer case studies on using AI to organize work across external laboratories. Whether those examples lead to faster development, better outcomes or lower costs is not established by the information available about Mithril.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
Hyperice Hypervolt 3 Pro Percussion Massage Gun with Heated Head and Carry Case
As an affiliate, we earn on qualifying purchases.
Anthropic’s Earlier Life-Sciences Moves
Mithril is not Anthropic’s only biotech-related acquisition reported this year. PYMNTS said the company bought Coefficient Bio, a startup of fewer than 10 people that was developing tools to plan drug research and manage clinical regulatory strategy. The report put the purchase price at about $400 million.
The acquisition also comes as Anthropic identifies life sciences as a target market. Its S-1 filing, dated Oct. 26, lists healthcare and life sciences first among the new markets it intends to enter. The filing says nine of the 10 largest pharmaceutical companies are customers, without naming them. The source report also cited a PYMNTS survey of 60 senior technology executives at large U.S. companies: 84% of healthcare firms expected to raise AI spending over the following 12 months, and none expected to cut it.
Other AI companies are pursuing different parts of drug development. PYMNTS reported that OpenAI agreed Oct. 20 to acquire Orchestra Bio, whose agents track study progress and timelines. That deal concerns workflow monitoring; Anthropic’s Mithril acquisition involves running early drug programs itself.
“Running real drug programs shows where Claude holds up and where it fails.”
— Anthropic, as described in the PYMNTS report
Human Testing Remains Years Away
The report does not identify the two muscular dystrophy forms, provide detailed data from the mouse tests, or state how many candidates are in Mithril’s programs. It also does not provide independent evidence that Claude itself generated the candidate or caused the reported research progress. The described role includes organizing and coordinating work across labs and business functions.
It remains unclear whether regulators will authorize a human trial, whether the candidate will be ready on Anthropic’s projected timetable, and whether results in mice will translate to people. The acquisition price for Mithril was not provided in the source material. Anthropic’s planned further programs and how Claude will be used as research advances have not been detailed.
More Programs Before Clinical Trials
Tranbarger is expected to begin several more programs at Anthropic, while the company says it will extend Claude’s role as Mithril’s research advances. The next major test will be whether the preclinical work produces enough evidence to support moving a candidate toward human studies.
Anthropic has given late 2028 as the earliest possible point for a drug to be ready for human trials. That remains a company projection. The source material does not specify a trial start date, regulatory decisions, or further public milestones, so the timing and outcome remain uncertain.
Key Questions
What did Anthropic acquire?
Anthropic said it acquired Mithril Medicine, a startup developing treatments for two rare forms of muscular dystrophy. Its founder, Cody Tranbarger, has joined Anthropic.
How did Mithril use Claude?
Tranbarger used Claude to organize contracts, logistics and experiments across 11 external labs and delegated other business tasks to the model, according to the report.
Has Mithril’s candidate been tested in people?
No human testing is reported. The lead antibody has been tested only in mice, and Anthropic says the programs remain mostly preclinical.
When could a human trial begin?
Anthropic said a drug could be ready for human trials as soon as late 2028. That is a projected possibility, not a confirmed trial date or regulatory approval.
Why is Anthropic running drug programs?
Anthropic said the programs will help it learn where Claude performs well and where it fails, provide case studies for other biotech companies, and potentially produce medicines if the candidates work.
Source: pymnts.com
